Literature DB >> 15102433

IkappaB kinases: key regulators of the NF-kappaB pathway.

Yumi Yamamoto1, Richard B Gaynor.   

Abstract

The nuclear factor (NF)-kappaB pathway is important for the expression of a wide variety of genes that are involved in the control of the host immune and inflammatory response, and in the regulation of cellular proliferation and survival. The constitutive activation of this pathway is associated with inflammatory and autoimmune diseases, such as asthma, rheumatoid arthritis and inflammatory bowel disease, in addition to atherosclerosis, Alzheimer's disease, cancer and diabetes. One of the key steps in activating the NF-kappaB pathway is the stimulation of the IkappaB (inhibitor of kappaB) kinases. Recent data indicate that these kinases activate the NF-kappaB pathway through distinct steps that are operative in both the cytoplasm and the nucleus. A better understanding of the mechanisms that activate this pathway provides the potential for defining new therapeutic targets that might prevent the aberrant activation of NF-kappaB in a variety of human diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102433     DOI: 10.1016/j.tibs.2003.12.003

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  185 in total

1.  Breaking the NF-κB and STAT3 alliance inhibits inflammation and pancreatic tumorigenesis.

Authors:  Young-Joon Surh; Ann M Bode; Zigang Dong
Journal:  Cancer Prev Res (Phila)       Date:  2010-10-26

2.  Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity.

Authors:  Eoin P Cummins; Edurne Berra; Katrina M Comerford; Amandine Ginouves; Kathleen T Fitzgerald; Fergal Seeballuck; Catherine Godson; Jens E Nielsen; Paul Moynagh; Jacques Pouyssegur; Cormac T Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-17       Impact factor: 11.205

3.  Nuclear factor κB subunits RelB and cRel negatively regulate Toll-like receptor 3-mediated β-interferon production via induction of transcriptional repressor protein YY1.

Authors:  Jakub Siednienko; Ashwini Maratha; Shuo Yang; Malgorzata Mitkiewicz; Sinéad M Miggin; Paul N Moynagh
Journal:  J Biol Chem       Date:  2011-11-07       Impact factor: 5.157

4.  Persistent nuclear factor-kappa B activation in Ucp2-/- mice leads to enhanced nitric oxide and inflammatory cytokine production.

Authors:  Yushi Bai; Hiroki Onuma; Xu Bai; Alexander V Medvedev; Mary Misukonis; J Brice Weinberg; Wenhong Cao; Jacques Robidoux; Lisa M Floering; Kiefer W Daniel; Sheila Collins
Journal:  J Biol Chem       Date:  2005-03-09       Impact factor: 5.157

5.  Regulation of RelB expression during the initiation of dendritic cell differentiation.

Authors:  Pedro J Cejas; Louise M Carlson; Despina Kolonias; Jian Zhang; Inna Lindner; Daniel D Billadeau; Lawrence H Boise; Kelvin P Lee
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

6.  NF-kappaB activation during Rickettsia rickettsii infection of endothelial cells involves the activation of catalytic IkappaB kinases IKKalpha and IKKbeta and phosphorylation-proteolysis of the inhibitor protein IkappaBalpha.

Authors:  Dawn R Clifton; Elena Rydkina; Robert S Freeman; Sanjeev K Sahni
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

7.  CD46-utilizing adenoviruses inhibit C/EBPbeta-dependent expression of proinflammatory cytokines.

Authors:  Milena Iacobelli-Martinez; Ronald R Nepomuceno; Jodi Connolly; Glen R Nemerow
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  Effects of IkappaBalpha and its mutants on NF-kappaB and p53 signaling pathways.

Authors:  Xian Li; Da Xing; Ju Wang; De-Bin Zhu; Lan Zhang; Xiao-Jia Chen; Fen-Yong Sun; An Hong
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

9.  A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity.

Authors:  Karl Ziegelbauer; Florian Gantner; Nicholas W Lukacs; Aaron Berlin; Kinji Fuchikami; Toshiro Niki; Katsuya Sakai; Hisayo Inbe; Keisuke Takeshita; Mina Ishimori; Hiroshi Komura; Toshiki Murata; Timothy Lowinger; Kevin B Bacon
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

10.  Anti-inflammatory effect of a selective IkappaB kinase-beta inhibitor in rat lung in response to LPS and cigarette smoke.

Authors:  Saravanan Rajendrasozhan; Jae-Woong Hwang; Hongwei Yao; Nandini Kishore; Irfan Rahman
Journal:  Pulm Pharmacol Ther       Date:  2010-01-18       Impact factor: 3.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.